Analysis of the current Covid-19 infection and vaccination status in patients with neurofibromatosis type 1

Aboueshia, 2021, Cancer and COVID-19: analysis of patient outcomes, Future Oncol, 17, 3499, 10.2217/fon-2021-0121 2022, Chinese expert consensus on issues related to the protection, treatment and management of patients with solid tumors during COVID-19 (2022 edition), Chin J Oncol, 44, 1083 Hirbe, 2014, Neurofibromatosis type 1: a multidisciplinary approach to care, Lancet Neurol, 13, 834, 10.1016/S1474-4422(14)70063-8 Friedman, 1999, Epidemiology of neurofibromatosis type 1, Am J Med Genet, 89, 1, 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8 Ly, 2019, The diagnosis and management of neurofibromatosis type 1, Med Clin, 103, 1035 Guan, 2020, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, 382, 1708, 10.1056/NEJMoa2002032 Kouhpayeh, 2022, Adverse events following COVID-19 vaccination: a systematic review and meta-analysis, Int Immunopharm, 109, 10.1016/j.intimp.2022.108906 Tran, 2021, Evaluation of COVID-19 vaccine response in patients with cancer: an interim analysis, Eur J Cancer, 159, 259, 10.1016/j.ejca.2021.10.013 Karmakar, 2017, The role of the immune system in neurofibromatosis type 1-associated nervous system tumors, CNS Oncol, 6, 45, 10.2217/cns-2016-0024 Fletcher, 2019, After Nf1 loss in Schwann cells, inflammation drives neurofibroma formation, Neurooncol Adv, 2, i23 Wang, 2020, Acceptance of COVID-19 vaccination during the COVID-19 pandemic in China, Vaccines (Basel), 8, 482, 10.3390/vaccines8030482 Banerjee, 2023, COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis, Genet Med, 25, 10.1016/j.gim.2022.10.007 Han, 2021, COVID-19 and cancer: from basic mechanisms to vaccine development using nanotechnology, Int Immunopharm, 90, 10.1016/j.intimp.2020.107247 Desai, 2021, COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials, Nat Rev Clin Oncol, 18, 313, 10.1038/s41571-021-00487-z He, 2021, COVID-19 vaccine development from the perspective of cancer patients, Hum Vaccines Immunother, 17, 3281, 10.1080/21645515.2021.1943988 Mandal, 2021, Vaccination of cancer patients against COVID-19: towards the end of a dilemma, Med Oncol, 38, 92, 10.1007/s12032-021-01540-8